ReviewInternational journal of molecular sciences2023
Clinical Trials with Mesenchymal Stem Cell Therapies for Osteoarthritis: Challenges in the Regeneration of Articular Cartilage.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 78 citations in OpenAlex.
- Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.Cell transplantationTrial
- Engineered Injectable Hydrogel Platform for Tailoring the Osteoarthritis Microenvironment.Advanced healthcare materials · 2026Review
- Combining polydioxanone-based scaffold and allogeneic adipose-derived mesenchymal stem cells enhances articular cartilage repair - a pre-clinical study.Journal of orthopaedic translation · 2026Article
- Cryogel-based therapeutic platforms for disease modification in osteoarthritis.npj biomedical innovations · 2026Review
- Adipose-Derived Stromal Cells for the Treatment of Knee Osteoarthritis: A Retrospective Study of Clinical Outcomes and Predictive Factors.Healthcare (Basel, Switzerland) · 2026Article
- Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases.Stem cell reviews and reports · 2026Review
- Challenges and Strategies in Hydrogel-Based Cartilage Regeneration.Gels (Basel, Switzerland) · 2026Review
- Spine-Related Health Care Utilization and Costs Following Orthobiologic Injection Versus Lumbar Surgery for Degenerative Spine Conditions.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Recombinant Human Amelogenin Protein Enhances Healing of Osteochondral Injury in a Goat Model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
- Managing Osteoarthritis Pain in Underrepresented Populations: Insights from Mexico and Latin America.Journal of clinical medicine · 2026Review
- Chondrocyte Senescence in Osteoarthritis: Potential Targets and Pharmacological Interventions.Cartilage · 2026Article
- Large-Scale Production of Secretome From Human Dental Pulp Stem Cells for Articular Cartilage Regeneration.Stem cells international · 2026Article
- New therapeutic target for osteoarthritis: modulating immune-metabolic aberrations and micromilieu remodeling in underlying bone.Frontiers in pharmacology · 2026Review
- Immunomodulatory therapies for osteoarthritis: from bench to bedside.Annals of joint · 2026Review
- Optimizing Osteoarthritis Management - Therapeutic Efficacy and Evaluation of Intra-Articular Triamcinolone Acetonide Injection.Journal of pain research · 2026Review
- Targeting synovial inflammation in knee osteoarthritis: translational insights for diagnosis and therapy.Journal of orthopaedic translation · 2026Review
- High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.Frontiers in bioengineering and biotechnology · 2026Article
- Comparative analysis of scaffold-free tissue-engineered cartilage derived from different seed cells: in vitro and in vivo studies.Stem cells translational medicine · 2025Article
- Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial.Stem cell research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a whole-joint disease primarily characterized by the deterioration of hyaline cartilage. Current treatments include microfracture and chondrocyte implantation as early surgical strategies that can be combined with scaffolds to repair osteochondral lesions; however, intra-articular (IA) injections or implantations of mesenchymal stem cells (MSCs) are new approaches that have presented encouraging therapeutic results in animal models and humans. We critically reviewed clinical trials with MSC therapies for OA, focusing on their effectiveness, quality, and outcomes in the regeneration of articular cartilage. Several sources of autologous or allogeneic MSCs were used in the clinical trials. Minor adverse events were generally reported, indicating that IA applications of MSCs are potentially safe. The evaluation of articular cartilage regeneration in human clinical trials is challenging, particularly in the inflammatory environment of osteoarthritic joints. Our findings indicate that IA injections of MSCs are efficacious in the treatment of OA and the regeneration of cartilage, but that they may be insufficient for the full repair of articular cartilage defects. The possible interference of clinical and quality variables in the outcomes suggests that robust clinical trials are still necessary for generating reliable evidence with which to support these treatments. We suggest that the administration of just-sufficient doses of viable cells in appropriate regimens is critical to achieve effective and durable effects. In terms of future perspectives, genetic modification, complex products with extracellular vesicles derived from MSCs, cell encapsulation in hydrogels, and 3D bioprinted tissue engineering are promising approaches with which to improve MSC therapies for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.